Generating real-world external comparators (rwECs) for randomized clinical trials (RCTs) in metastatic breast cancer (mBC) using electronic health records (EHRs) Published December 2021 Citation Amiri-Kordestani, L, Gao, X, Baxi, SS, Bloomquist, E, Bryan, J, Howie, L, Keane, C, Kluetz, P, Osgood, C, Paliwal, P, Rivera, DR, Roose, JP, Schneider, J, Ssingh, H, Tang, S, Zhang, L, Beaver, J. . SABCS. . https://www.sabcs.org/Program/Poster-Sessions/Poster-Session-2 Authors:Amiri-Kordestani, L, Gao, X, Baxi, SS, Bloomquist, E, Bryan, J, Howie, L, Keane, C, Kluetz, P, Osgood, C, Paliwal, P, Rivera, DR, Roose, JP, Schneider, J, Ssingh, H, Tang, S, Zhang, L, Beaver, J Sources:San Antonio Breast Cancer Symposium Share Posted inPublicationsMethodologyComparative effectivenessMetastatic breast cancer More publicationsESMO OpenSeptember 2025Real-world progression-free survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR-positive/HER2-negative metastatic breast cancer in United States routine clinical practiceRugo H, Layman R, Lynce F, et al.Publication summaryPublicationsComparative effectivenessMetastatic breast cancerBreast cancerASCO Annual MeetingMay 2026Comparison of real-world overall survival between atezolizumab- and durvalumab-containing first- line induction and maintenance regimens in extensive-stage small cell lung cancerGanti AK, Snider J, Yan J, et al.Publication summaryPublicationsComparative effectivenessSmall cell lung cancerASCO Annual MeetingMay 2026Using ML to predict rapid progression for patients (pts) with HR+/HER2- metastatic breast cancer (mBC) treated with frontline (1L) CDK 4/6 inhibitors (CDK 4/6i)Peng M, Rios G, Estevez M, et al.Publication summaryPublicationsPrecision medicineMachine learningMetastatic breast cancerArtificial intelligence